The AI startup dilemma: To pivot or perish
Empower your mind, elevate your skills
In the last few weeks, four Indian AI startups have announced that they are shutting in the face of challenges such as scaling up, raising funds and pivoting as technology shifts rapidly. This includes two Y-Combinator companies Wuri and CodeParrot as well as Subtl.ai and Locale.ai. This is not unusual in the world of startups. According to the US Bureau of Labor Statistics, more than 50% of the startups fail within five years.However, unlike the previous cycles, beyond operational challenges, these closures are coming amid rapid technological development in artificial intelligence.'Startups are shutting down quicker compared to before,' said a Bengaluru-based investor. Unlike previous technology cycles during which founders could continue running businesses for longer until they found the right fit, many now realize it's better to shut down and start afresh than burn money. AI startups for instance are being rendered obsolete, Tencent Investments managing partner Jeffrey Li told a recent conference.Case in point, the sheer number of AI tools that are going out of the market. AI tool aggregation platform Dang.ai said that of the 4,956 added, 1,301 have been terminated. In 2025, 227 AI tools ceased operations. In order to win in the age of AI, startups should pivot fast as the technology becomes more commoditised, experts said. While technology is important, it's key to focus on the problem that's to be solved.'Right now is a very difficult time to be a founder because the developments are happening at such a rapid pace,' said Akshay Megharaj, founder of Wuri. People always seek inspiration from past experience, which is not possible due to the sheer nature of how the technology is developing, he said.'As much as artificial intelligence has made it easy to build products, the rapidly evolving technology is also making it challenging for startups to have a right to win,' said Naman Maheshwari, co-founder, Tune AI, an orchestration platform that closed recently. This means that companies need to pivot and fast, to stay relevant.Speed, more than anything, is a primary moat in the world of AI, said Sanjay Nath, co-founder and partner, Blume Ventures. He explained that even if a startup has a great product, if they don't keep pace with technology, they will be left behind by competitors, who may have 20% inferior product but execute 50% faster.Gandhi said, 'A large percentage of companies that we back at seed end up pivoting, and the ones that are agile and keep evolving are the ones that are likely to succeed in this crazy, fast-flowing environment.'The key is to find the right problem to solve.To build enduring companies, startups need to solve fundamental issues in the areas of healthcare, climate and sustainability, Google country manager Preeti Lobana said at the recently concluded Google I/O event in Bengaluru. A Bengaluru-based investor said, 'For most startups, AI is mostly an add-on. They need to ask themselves this question — are you solving a problem even if you take AI out of the equation.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
14 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
The Hindu
44 minutes ago
- The Hindu
After Prada controversy, LIDCOM and LIDKAR reaffirm ownership of Kolhapuri Chappal GI Tag
Days after the Prada controversy about Kolhapuri chappals, and after a business body from Maharashtra engaged in discussion with Prada, Maharashtra-based LIDCOM and Karnataka-based LIDKAR have reaffirmed their ownership of the Geographical Indication (GI) tag for Kolhapuri chappals. 'No individual or organization other than us is authorized to engage in any discussion, negotiation, or representation with Prada or similar international entities,' a press release issued jointly on Friday (August 1, 2025) by LIDCOM Managing Director Prerna Deshbhratar and LIDKAR Managing Director K.M. Vasundhara stated. 'The traditional and historic Kolhapuri chappal, originating from Maharashtra and Karnataka, has been granted the Geographical Indication (GI) tag. The officially registered ownership of this GI tag rests solely with two corporations—Sant Rohidas Leather Industries and Charmakar Development Corporation Limited (LIDCOM) and Dr. Babu Jagjivanram Leather Industries Development Corporation Limited (LIDKAR)—as clarified by the Managing Directors of both entities,' it stated. Kolhapuri chappals, which received royal patronage in the 20th century under Chhatrapati Shahu Maharaj, were made in the erstwhile province under the king. Today, these parts of the earlier province are spread across eight districts. Four of them are in Maharashtra, and four in Karnataka. The tradition of the chappals dates back to the 12th century saint tradition. In June 2025, the renowned Italian fashion brand Prada presented its Spring/Summer 2026 men's collection. 'Observers noted that the leather sandals worn by a model in this show bore a striking resemblance to the GI-tagged traditional Kolhapuri chappals from Maharashtra. This resemblance sparked strong reactions on social media platforms and among traditional artisan communities. Following the incident, a group of lawyers filed a Public Interest Litigation (PIL) in the Bombay High Court, alleging that Prada's use of a design protected under GI registration constituted a violation of intellectual property laws. On July 16, 2025, the court dismissed the PIL, stating that in such matters, only the registered GI holders—namely, the leather industry development corporations of Maharashtra and Karnataka—are the legitimate stakeholders and hence, solely entitled to initiate any civil legal proceedings,' the press release said. They said that their collective mission goes beyond protecting the geographical indication. 'It is also aimed at safeguarding the rights of thousands of local leather artisans and firmly establishing this heritage on national and international platforms.'
